Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$2.78
-0.19 (-6.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $211.2M · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
5.0x
↓EV/EBITDA
2.4x
↓ROE
13.2%
↑Gross Margin
89.2%
↑Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.2%
FCF CAGR
+9.7%
FCF margin
7.3%
FCF / Net income
0.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.81B · net income $318.1M · FCF $131.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.81B | $1.81B | $1.67B | $1.74B | $1.32B |
| Net Income | $318.1M | $318.1M | $307.2M | $275.3M | $225.4M |
| EBITDA | $485.1M | $485.1M | $437.5M | $417.1M | $313.7M |
| EPS | — | — | 0.53 | 0.47 | 0.38 |
| Gross Margin | 89.2% | 89.2% | 89.8% | 89.9% | 90.3% |
| Operating Margin | 22.8% | 22.8% | 21.3% | 19.3% | 21.4% |
| Net Margin | 17.5% | 17.5% | 18.4% | 15.8% | 17.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.14 | 0.14 | 0.09 | 0.15 | 0.28 |
| Current Ratio | 2.11 | 2.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $131.7M | $131.7M | $249.0M | $211.2M | $99.9M |
| Returns | |||||
| ROE | 13.2% | 13.2% | 14.5% | 14.3% | 13.0% |
| Valuation | |||||
| P/E | 5.02 | 5.02 | 5.38 | 5.22 | 10.61 |
| EV/EBITDA | 2.39 | 2.39 | 2.96 | 2.98 | 7.59 |
| P/B | 0.66 | 0.66 | 0.78 | 0.76 | 1.41 |
| Growth & Yield | |||||
| Revenue Growth | 8.6% | 8.6% | -3.9% | 31.8% | — |
| EPS Growth | — | — | 13.4% | 22.5% | — |
| Dividend Yield | 4.7% | 4.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.53 → n/d
Residual
-45.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.